These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29420319)

  • 1. Rivaroxaban for Left Ventricular Thrombus.
    Yassin AS; Abubakar H; Mishra T; Adam O; Hartman M; Pahuja M; Shokr M
    Am J Ther; 2019; 26(4):e511-e515. PubMed ID: 29420319
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban Used for Treatment of a Left Ventricular Thrombus in a Patient With Nonischemic Cardiomyopathy.
    Abubakar H; Yassin AS; Shokr M
    Am J Ther; 2018; 25(6):e706-e709. PubMed ID: 29324466
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of rivaroxaban in left ventricular thrombi.
    Abdelnaby M; Almaghraby A; Abdelkarim O; Saleh Y; Hammad B; Badran H
    Anatol J Cardiol; 2019 Jan; 21(1):47-50. PubMed ID: 30587707
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.
    Smetana KS; Dunne J; Parrott K; Davis GA; Collier ACS; Covell M; Smyth S
    J Thromb Thrombolysis; 2017 Nov; 44(4):519-524. PubMed ID: 28948507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality.
    Esteve-Pastor MA; Orenes-Piñero E; Roldán V; Lacunza-Ruiz J; Valdés M; Marín F
    Cardiol J; 2018; 25(1):151-154. PubMed ID: 29512103
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban for cancer-associated cardiac thrombosis.
    Di Nisio M; Carella C; Natoli C; Porreca E; De Tursi M
    Am J Med; 2015 Oct; 128(10):e43-4. PubMed ID: 26071831
    [No Abstract]   [Full Text] [Related]  

  • 7. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).
    Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; van Eickels M; Cohen A;
    Am Heart J; 2016 Aug; 178():126-34. PubMed ID: 27502860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanical Valve Thrombosis on Rivaroxaban: Are Novel Anticoagulants Really an Option?
    Kumar V; Kelly S; Raizada A; Yee J; Anuwatworn A; Stys A; Stys M
    Methodist Debakey Cardiovasc J; 2017; 13(2):73-75. PubMed ID: 28740586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban.
    Htut TW; Milne D; Khan MM; Watson HG
    Int J Lab Hematol; 2021 Oct; 43(5):e252-e253. PubMed ID: 33470532
    [No Abstract]   [Full Text] [Related]  

  • 10. Resolution of left ventricular thrombus by rivaroxaban.
    Padilla Pérez M; Salas Bravo D; Garcelán Trigo JA; Vazquez Ruiz de Castroviejo E; Torres Llergo J; Lozano Cabezas C; Fernández Guerrero JC
    Future Cardiol; 2014 May; 10(3):333-6. PubMed ID: 24976470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanical Prosthetic Heart Valve Thrombosis in a Patient Receiving Rivaroxaban.
    Carvalho Silva DM; Braga A; de Jesus I; Neves J
    Cardiology; 2019; 143(3-4):116-120. PubMed ID: 31473736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report.
    Sun H; Zhao Q; Wang Y; Lakin R; Feng H; Fan X; Luo H; Gao D; Liu L; He Y; Yang P
    Medicine (Baltimore); 2018 Jan; 97(4):e9670. PubMed ID: 29369185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin-resistant left ventricular thrombus completely dissolved by rivaroxaban.
    Huang LY; Chang TH; Wu CH; Tsai TN
    Br J Hosp Med (Lond); 2018 Nov; 79(11):648-649. PubMed ID: 30418821
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
    Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; Morandi E; van Eickels M; Cohen A
    Am Heart J; 2015 Apr; 169(4):464-71.e2. PubMed ID: 25819852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient.
    Saito S; Tomita H; Kimura Y; Shiroto H; Hagii J; Metoki N; Hitomi H; Kamada T; Osanai T; Okumura K; Yasujima M
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1747-9. PubMed ID: 24725815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analysis Comparing the Effect of Rivaroxaban Versus Vitamin K Antagonists for Treatment of Left Ventricular Thrombi.
    Saleh Y; Al-Abcha A; Abdelkarim O; Elwany M; Abdelfattah OM; Abdelnabi M; Almaghraby A
    Am J Cardiol; 2021 Dec; 161():123-125. PubMed ID: 34656296
    [No Abstract]   [Full Text] [Related]  

  • 17. Late Obstructive Transcatheter Heart Valve Thrombosis Resolved by Rivaroxaban.
    Mathiassen ON; Grove EL; Hansson NC; Norgaard BL
    Am J Case Rep; 2017 May; 18():573-575. PubMed ID: 28536415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option.
    Piotrowski R; Zaborska B; Baran J; Sikora-Frąc M; Kułakowski P
    Pol Arch Med Wewn; 2016 Jun; 126(6):430-1. PubMed ID: 27305139
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of non-vitamin K antagonist oral anticoagulants on left atrial or atrial appendage thrombi in patients with nonvalvular atrial fibrillation].
    Cui J; Du X; Wu JH; Jia CQ; Li X; Ning M; Lyu J; Yang Y; Liu XH; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Aug; 46(8):606-610. PubMed ID: 30139010
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.